IIIdanna Innocenti

Idanna Innocenti

*This is an algorithmically generated author record based on publicly available information.

Idanna Innocenti has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management

    by Eugenio Galli, Alberto Fresa, Silvia Bellesi, Elisabetta Metafuni, Elena Maiolo, Ilaria Pansini, Filippo Frioni, Francesco Autore, Maria Assunta Limongiello, Idanna Innocenti, et al.

    Impaired function of hematopoiesis after treatment with chimeric antigen T‐cells (CAR‐T) is a frequent finding and can interest a wide range of patients, regardless of age and underlying disease. Trilinear cytopenias, as well as hypogammaglobulinemia, B‐cell aplasia, and T‐cell impairment, can severely affect the infectious risk of CAR‐T recipients, as well as their quality of life. In this review, we provide an overview of defects in hematopoiesis after CAR‐T, starting with a summary of different definitions and thresholds. We then move to summarize the main pathogenetic mechanisms of cytopenias, and we offer insight into cytomorphological aspects, the role of clonal hematopoiesis, and the risk of secondary myeloid malignancies. Subsequently, we expose the major findings and reports on T‐cell and B‐cell quantitative and functional impairment after CAR‐T. Finally, we provide an overview of current recommendations and leading experiences regarding the management of cytopenias and defective B‐ and T‐cell function.


  • Open Access

    Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti‐CD19 CAR‐T cells

    by Eugenio Galli, Federica Sorà, Stefan Hohaus, Alberto Fresa, Ilaria Pansini, Francesco Autore, Elisabetta Metafuni, Idanna Innocenti, Maria Assunta Limongiello, Sabrina Giammarco, et al.

    Summary: Cytokine release syndrome (CRS) and consumptive coagulopathy can complicate the treatment with chimeric antigen receptor T (CAR‐T) cells. The modified version of the Endothelial Activation and Stress Index (mEASIX), a score derived from haematopoietic stem cell transplantation, combines platelets, C‐reactive protein (CRP), and lactate dehydrogenase (LDH) and has been correlated with CRS and endothelial biomarkers. In 38 consecutive patients with aggressive lymphoproliferative disease we measured a coagulative laboratory panel at baseline and early after infusion of anti‐CD19 CAR‐T. The panel was investigated also in the presence of CRS graded 2 or higher, or immune effector cell‐associated neurotoxicity syndrome (ICANS). Moreover, we examined the relationship between mEASIX, coagulation biomarkers, and toxicities of CAR‐T cells. During CRS grade 2 or higher, we found increased prothrombin time (PT) and activated partial thromboplastin time (aPTT), fibrinogen, D‐dimer, factor VIII (FVIII), and von Willebrand factor (vWF) antigen levels, and decreased platelet count and antithrombin levels. The occurrence of immune effector cell‐associated neurotoxicity syndrome was associated with higher PT values, D‐dimer, FVIII, and vWF levels, and decreased fibrinogen levels and platelet count. A higher mEASIX score correlated with increased aPTT values, fibrinogen, D‐dimer, FVIII and vWF levels, and decreased antithrombin levels. Baseline mEASIX was predictive for consumptive coagulopathy and CRS graded 2 or higher, and for progression‐free survival and overall survival.


  • Open Access

    Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant

    by Federica Sora, Sabrina Giammarco, Anna Maria Raiola, Carmen Di Grazia, Stefania Bregante, Francesca Gualandi, Riccardo Varaldo, Patrizia Chiusolo, Simona Sica, Luca Laurenti, et al.


  • Open Access

    Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study

    by Alberto Fresa, Francesco Autore, Alfonso Piciocchi, Gioacchino Catania, Andrea Visentin, Annamaria Tomasso, Marina Moretti, Candida Vitale, Annalisa Chiarenza, Francesca Morelli, et al.


  • Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomas

    by Francesco Autore, Alberto Fresa, Idanna Innocenti, Maria Ilaria Del Principe, Raffaele Maglione, Caterina Stefanizzi, Sabrina Pelliccia, Azzurra Romeo, Giuseppe Cimino, Elena Papa, et al.

    Takezaki et al. analyzed the outcome of 57 patients with indolent lymphomas treated with Bendamustine plus Rituximab (BR) according to the number of cycles received, showing that patients who discontinued BR after four cycles had similar outcomes compared to patients who received five or six cycles. Considering the similarities but also the differences between indolent lymphomas and chronic lymphocytic leukemia (CLL), we enriched the results obtained with a cohort of CLL patients treated with BR starting from the experience of the Lazio region group on CLL. Out of 115 patients, 97 (84%) received 4–6 cycles of BR, while 18 (16%) received 1–3 cycles. The outcome of the group of patients who received at least 4 cycles was superior in terms of response rate (ORR 96% vs. ORR 83%, p = 0.041; CR 58% vs. CR 28%, p = 0.052 respectively) and PFS [median PFS 52.6 (40.3–64.9) versus 26.2 (19.3–33.0) months, p < 0.001]. The number of patients undergoing 4 cycles of BR (4‐cycles group) and 5–6 cycles (over‐4‐cycles group) was 9 and 88, respectively. Compared to analysis conducted by the Japanese group in indolent lymphomas, in CLL we did not observe any difference between the outcome of the 4‐cycles group and the over‐4‐cycles group in terms of ORR (89% vs. 97%, p = 0.268) and in survival [median PFS 40.8 (13.7–67.8) versus 52.6 (38.7–66.5) months, p = 0.117]. Moreover, we observed that patients who achieved a clinical CR showed overlapping outcomes with patients who received more than 4 cycles [CR vs. non‐CR median PFS not reached vs. 11.0 months; over‐4‐cycles group median PFS 52.6 months (40.3–64.9); p < 0.001]. Nowadays chemoimmunotherapy with BR is reserved to fit elderly CLL patients, and there are many chemo‐free treatment options available; therefore, discontinuation after 4 cycles may be permissible in patients who obtained a CR in order to limit toxicity as much as possible.


  • Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma

    by Eugenio Galli, Federica Sorà, Stefan Hohaus, Silvia Bellesi, Francesco Autore, Elisabetta Metafuni, Idanna Innocenti, John Marra, Alberto Fresa, Maria Assunta Limongiello, et al.


  • Open Access

    Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics

    by Idanna Innocenti, Annamaria Tomasso, Giulia Benintende, Francesco Autore, Alberto Fresa, Florenzia Vuono, Luca Stirparo, Eugenio Galli, Giovanni D’aRena, Federica Sorà, et al.

    Secondary antibody deficiency (SAD) is a frequent manifestation of chronic lymphocytic leukemia (CLL) that increases the risk of infections. However, no formal guideline are available regarding the eligibility for prophylaxis or the delivery method, dosage, frequency of administration and duration of immunoglobulin replacement therapy (IgRT). The aim of this study was to assess the efficacy and safety of subcutaneous IgRT (SCIg) and its impact on quality of life (QoL) of CLL pts in the Covid‐19 era. Ten CLL pts with SAD were treated with subcutaneous IgRT (SCIg) at our institution between October 2019 and December 2020. Median age was 66 years and five patients had comorbidities. Seven patients were receiving therapy for CLL when treatment with SCIg was initiated. All pts received 10 g total dose hyaluronidase‐free SCIg independently from body weight. The IgG level and CD4/CD8, CD19 and CD16/56 lymphocytes subset were recorded at baseline and every 3 months. No patient experienced infectious events nor Covid‐19 mediated interstitial pneumonia while on SCIg therapy. All patients tolerated well the therapy and experienced an increase of IgG levels, which was then stable in time. We conclude that SCIg administration in CLL pts with SAD is efficacious and safe as infectious prophylaxis. This route of administration appears particularly advantageous in the Covid‐19 era, because of the self‐administration at home which results in improvement in the QoL and reduced treatment expenditures.


  • Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b‐precursor acute lymphoblastic leukaemia: Case reports and literature review

    by Federica Sora, Mario Annunziata, Luca Laurenti, Sabrina Giammarco, Patrizia Chiusolo, Idanna Innocenti, Francesco Autore, Elisabetta Metafuni, Eugenio Galli, Andrea Bacigalupo, et al.


  • Open Access

    Combined Genetic Lesions in TP53 and CDKN2A/CDKN2B Drive B Cell Receptor-Dependent/Costimulatory Signal-Independent Proliferation in Richter Syndrome

    by Supriya Chakraborty, Claudio Martines, Fabiola Porro, Ilaria Fortunati, Alice Bonato, Marija Dimishkovska, Brijesh Yadav, Idanna Innocenti, Rosa Fazio, Tizianna Vaisitti, et al.

    B cell receptor (BCR) signals play a critical role in the pathogenesis of chronic lymphocytic leukemia (CLL), but their role in regulating CLL cell proliferation has still not been firmly established. Unlike normal B cells, CLL cells do not proliferate in vitro upon engagement of the BCR, suggesting that CLL cell proliferation is regulated by other signals from the microenvironment, such as those provided by Toll-like receptor (TLR) ligands or T cells. However, the rapid reduction in the percentage of proliferating CLL cells in patients treated with a BTK or SYK inhibitor suggests that the BCR may be more directly involved, at least in a subset of cases. To further address this issue, we investigated the expression of cell cycle regulatory proteins in human and Eμ-TCL1-derived murine CLL cells stimulated with immobilized anti-IgM or cognate antigen, respectively. In both cases, BCR stimulation induced the expression of the positive cell cycle regulators MYC, CCND1, CCND2 and CDK4, consistent with G1 cell cycle entry, but also induced the expression of the negative regulators CDKN1A, CDKN2A and CDKN2B, which block cell cycle progression. Since combined deficiency of these negative regulators occurs in approximately one quarter of Richter syndrome cases because of deletion of the CDKN2A/CDKN2B locus and inactivating genetic lesions of the CDKN1A regulator TP53, we introduced these defects by CRISPR/Cas9 in autoreactive murine Eμ-TCL1 leukemia cells and investigated the effects on leukemia behavior. Adoptive transfer experiments showed that combined targeting of TP53, CDKN2A and CDKN2B results in accelerated leukemia growth and morphological changes consistent with Richter's transformation, including more diffuse infiltration, larger and more pleomorphic cells, and a higher proliferation rate. Moreover, in vitro experiments showed that cells with combined TP53/CDKN2A/2B deficiency had acquired the capacity for spontaneous proliferation, in contrast to control, TP53- or CDKN2A/2B-targeted cells which died after a couple of weeks in culture. Nucleotide sequencing of the TP53/CDKN2A/2B-targeted cells showed complete disappearance of the wild type alleles, suggesting that biallelic loss of all three genes is required for spontaneous growth in vitro. Combined disruption of TP53, CDKN2A and CDKN2B in two other autoreactive Eμ-TCL1 leukemias yielded the same results. To determine whether the spontaneous in vitro proliferation is dependent on BCR signals, the TP53/CDKN2A/2B-deficient cells were transfected with Cas9 ribonucleoprotein complexes targeting the IgM heavy chain constant region (IGHM) gene or were treated with the BCR inhibitors ibrutinib, idelalisib and fostamatinib. Disruption of the IGHM gene or treatment with a BCR inhibitor resulted in almost complete block of proliferation. In contrast, knockdown of the TLR-adaptor protein MyD88 had no effect. Considering that T cells were not present in the culture conditions, these experiments establish that proliferation of Eμ-TCL1 leukemia cells with biallelic TP53/CDKN2A/2B disruption is BCR-dependent but independent of costimulatory signals. To validate these findings in a human setting, we performed experiments with two recently established Richter syndrome patient-derived xenografts, one with biallelic inactivation/deletion of TP53, CDKN2A and CDKN2B (RS9737), and one with wild type TP53, CDKN2A and CDKN2B (RS1316). BrdU incorporation experiments showed that only RS9737 cells proliferate in vitro following BCR stimulation, whereas both RS9737 and RS1316 cells proliferate following stimulation with CpG + IL-15 or CD40L + IL-4 + IL-21. Finally, we tested the activity of combined treatment with a BCR inhibitor and the CDK4/6 inhibitor palbociclib against the murine and human TP53/CDKN2A/2B-deficient Richter syndrome models. Combined treatment showed synergistic activity in vitro and significantly prolonged mouse survival in vivo compared to single agent treatment (n = 10 mice/group, P<0.001). In conclusion, these data provide evidence that BCR signals are directly involved in regulating CLL cell proliferation and suggest that frequently co-occurring genetic lesions in TP53 and CDKN2A/2B contribute to Richter transformation by allowing for BCR dependent/costimulatory signal independent proliferation, which can be therapeutically targeted with a BCR and CDK4/6 inhibitor combination.


  • Open Access

    A CRISPR/Cas9-Generated Murine Model Reveals Cooperation between BCR Signaling and CDKN2A/2B and TP53 Disruption in Richter Syndrome

    by Supriya Chakraborty, Ilaria Fortunati, Claudio Martines, Brijesh Yadav, Marija Dimishkovska, Idanna Innocenti, Rosa Fazio, Giovanni D'Arena, Aleksandar Dimovski, Luca Laurenti, et al.

    B cell receptor (BCR) signals generated by chronic interactions with external autoantigens or cell-autonomous BCR-BCR interactions play a critical role in the pathogenesis of CLL (Dühren-von Minden M et al, Nature 2012; Iacovelli S et al, Blood 2015). However, the role of these signals in regulating CLL cell responses and in particular in regulating CLL cell proliferation has still not been established. To address this issue, we first reanalyzed a previously generated dataset of human CLL cells stimulated with immobilized anti-IgM (Dal Bo M et al, Oncotarget 2015), which revealed differential expression of a number of genes involved in regulating the G1 phase of the cell cycle. The observed changes included upregulation of positive regulators of the cell cycle, such as CCND1, CCND2 and CDK4, but also upregulation of negative regulators, such as the cell cycle inhibitors CDKN1A, CDKN2A and CDKN2B. Changes in the expression of these genes were further validated by RQ-PCR analysis of a separate set of anti-IgM-stimulated human CLL cells (n=12), as well as by analysis of murine Eμ-TCL1-derived CLL cells stimulated with their cognate antigen phosphatidylcholine (PtC) (n=5). To investigate whether these genes are also induced by cell-autonomous BCR-BCR interactions, we analyzed the same samples following treatment with the SYK inhibitor entospletinib or the BTK inhibitor ibrutinib (1 μM each for 20 hours). A modest reduction in the levels of the cell cycle inhibitor CDKN2B but no change in the levels of any of the positive cell cycle regulators was observed, suggesting that only signals generated by external antigens can induce CLL cells to enter the cell cycle. The finding that the negative regulators CDKN1A, CDKN2A and CDKN2B are induced upon BCR engagement with external ligand appeared particularly interesting, considering that these genes are frequently downregulated in cases with Richter transformation because of co-existing genetic lesions in CDKN2A/2B and TP53, which is a key transcriptional activator of CDKN1A. Moreover, these findings suggested that genetic lesions in CDKN2A, CDKN2B and TP53 could contribute to Richter transformation by increasing the proliferation of leukemic cells stimulated with external autoantigen. To further address this possibility, we simultaneously targeted CDKN2A, CDKN2B and TP53 by CRISPR/Cas9 in primary Eμ-TCL1-derived murine CLL cells expressing an autoreactive BCR with specificity for the PtC autoantigen. The Cas9-edited and non-edited CLL cells were then expanded in immunodeficient NSG mice and were subsequently transferred in syngeneic recipients (n=6-8 per group) to evaluate the effects of CDKN2A/2B/TP53 knockdown on leukemia growth and proliferation. Combined targeting of CDKN2A, CDKN2B and TP53 resulted in accelerated leukemia growth, as evidenced by the significantly higher number of leukemic cells in the peritoneal cavity, peripheral blood and spleen of mice that received Cas9-edited vs wild type CLL cells (Figure 1A). The Cas9-edited leukemic cells showed markedly reduced expression of CDKN1A and CDKN2B protein (CDKN2A expression was not assessed in these experiments) and significantly higher expression of the proliferative markers Ki67, BrdU and phospho-histone H3 compared to non-edited leukemic cells. Moreover, indel analysis by amplicon capillary electrophoresis showed an increase in the ratio of CDKN2B mutant and TP53 mutant alleles vs wild type alleles during in vivo propagation, further suggesting that cells with combined CDKN2A/2B/TP53 deficiency have a growth advantage over wild type CLL cells (Figure 1B). A separate experiment with independent knockdown of CDKN2A/2B and TP53 also revealed selection of the mutant alleles during in vivo propagation, although only CDKN2A/2B knockdown resulted in a significant increase in tumor burden (Figure 1C and 1D). In conclusion, these data demonstrate that BCR interactions with external autoantigens induce both positive and negative regulators of the cell cycle and suggest that genetic lesions associated with Richter transformation cooperate with BCR signals by downregulating the negative regulators and facilitating cell cycle progression.